Response and Nippon Kayaku to develop PSA (prostate specific antigen) test:
This article was originally published in Clinica
Response Biomedical and Japanese company Nippon Kayaku are to collaborate on developing a prostate cancer test for use on Response's quantitative, point-of-care RAMP diagnostic system. The Vancouver, British Columbia company has signed an agreement with the Japanese partner, based in Tokyo, to make a test for the prostate cancer marker prostate specific antigen (PSA). Nippon Kayaku will fund the development and Japanese regulatory submission of the PSA test and will have sales and distribution rights for the product in Japan. Response reserves rights for other markets. The company has already developed a number of tests for other medical conditions for use on the RAMP assay.